Close Menu

NEW YORK – Cepheid said today that the US Food and Drug Administration has cleared its Xpert BCR-ABL Ultra test for monitoring disease burden in patients with chronic myeloid leukemia.

The in vitro diagnostic test can deliver accurate molecular results from whole blood samples in less than three hours, the company said in a statement. Measuring BCR-ABL gene transcript levels can indicate how well treatment for CML patients is working and predict relapses.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.